Patents by Inventor Angelina WALLIER

Angelina WALLIER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLO[2,3-B]PYRAZINE COMPOUNDS AS CCCDNA INHIBITORS FOR THE TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION
    Publication number: 20230248723
    Abstract: The present invention relates to novel therapeutic agents against hepatitis B virus (HBV) infection, particularly inhibitors of viral covalently closed circular DNA (cccDNA) which is the key barrier for HBV cure. Accordingly, the invention provides the pyrrolo[2,3-b]pyrazine compounds of formula (I), as described and defined herein, for use in the treatment of HBV infection. The compounds provided herein are highly potent against HBV infection and enable an improved therapy, particularly of chronic HBV infection and HBV rebound. The present invention further relates to a novel screening assay for the identification of therapeutic agents against HBV infection, particularly cccDNA inhibitors, which is performed in hepatocyte-like cells that recapitulate the complete HBV life cycle following infection with patient-derived HBV.
    Type: Application
    Filed: December 4, 2018
    Publication date: August 10, 2023
    Inventors: Jitao David ZHANG, Xingchun HAN, Song YANG, Miriam TRIYATNI, Brian LEONARD, Angelina WALLIER, Josephine SCHMALER, Daniel TURLEY, Philipp TROPBERGER, Samuel CROSET
  • OLIGONUCLEOTIDES FOR MODULATING RTEL1 EXPRESSION
    Publication number: 20210147850
    Abstract: The present invention relates to a RTEL1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of RTEL1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to antisense oligonucleotides which are complementary to RTEL1 and capable of reducing a RTEL1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.
    Type: Application
    Filed: January 13, 2021
    Publication date: May 20, 2021
    Inventors: Marco BERRERA, Josephine FELBER, Jean-Christophe HOFLACK, Susanne KAMMLER, Tony KAM-THONG, Brian LEONARD, Lykke PEDERSEN, Philipp TROPBERGER, Miriam TRIYATNI, Daniel Jeremy TURLEY, Angelina WALLIER, Jitao David ZHANG